Testimonials

Propath, a leading provider of molecular pathology and spatial biology services, adopted COMET™ to meet the growing demand for deeper biological insight from increasingly limited clinical trial samples. In this interview, Kelly Hunter, Chief Scientific Officer at Propath, explains how COMET™ fills the critical needs of delivering highly customizable, high‑plex panels without compromising quality, scalability, or turnaround time.

Fully-automated imaging and staining as well as seamless integration into Propath’s bioinformatics pipelines, accelerate multiplex assay development while ensuring consistent performance across long‑running, GCP‑compliant clinical programs. COMET’s gentle workflow preserves tissue integrity, enabling Propath to combine spatial proteomics and transcriptomics on the same precious tissue sections.

Biopharma and CRO partners rely on Propath’s COMET™‑enabled services to explore therapeutic mechanisms, understand cellular interactions, and uncover markers of response or resistance, all while maximizing insight from minimal tissue.

Key benefits for Propath and their clients:

• High throughput for rapid panel development and staining
• True multiomics with protein and RNA on the same slide
• Full flexibility to build custom or hybrid antibody panels
• Reproducibility at scale, even across multiple instruments

Learn more about Propath’s COMET™ services here.

Dr. Akil Merchant, physician and researcher at Cedars-Sinai, is advancing cancer research in the tumor microenvironment by integrating immuno-metabolic profiling at scale. His team designed an 82-marker immuno-metabolic panel using the COMET™ platform, bringing together markers of immune function, metabolism, and cellular signaling in one assay.

In this interview, Dr. Merchant dives into:

• How his lab’s approach balances depth and throughput;
• The role of full automation in ensuring consistent, reproducible results;
• Why COMET™ is uniquely suited for translational biomarker research.

Watch the full video to hear Dr. Merchant’s perspective on hyperplex spatial biology and its future impact on personalized cancer therapy.

We had the opportunity to speak with Dr. Hinda Najem, a Postdoctoral Research Fellow in the Department of Neurological Surgery at Northwestern University, about how the COMET™ platform has transformed her research. Dr. Najem dedicates her work to exploring spatial proteomics techniques to better understand primary and metastatic cancers of the central nervous system and complex brain diseases. She emphasizes the critical role that cutting-edge tissue profiling technologies, like COMET™, play in advancing  translational research and achieving impactful results. 

Watch the video to discover: 

• How Dr. Najem leverages COMET™ to enable rapid optimization of new antibodies, making it indispensable for time-sensitive projects; 

• Why COMET™’s hyperplexing capabilities have been a game-changer in expanding her research possibilities; 

• Why the platform stands out as the ideal choice for advancing translational research goals. 

With so many technologies to study spatial proteomics available on the market, it is hard to choose the best one for your needs. Listen to our exclusive interview with Dr. Andrew Filer, Head of the Birmingham Tissue Analytics Facility at the University of Birmingham, in which he explains why COMET™ is their go-to platform.

Play the video and discover:

• For what purpose, Dr. Andrew Filer recommends COMET™ to other core facilities, researchers, and clinicians.
• How COMET™ complements other technologies installed at the core facility in Birmingham.
• How COMET™ integrates into their core facility workflow.

• Why is multiplex immunofluorescence crucial to study viral infections and their effects on host cells?
• Why he would recommend COMET™ to other pathologists?
• What advice he would give to people getting into automated staining and imaging technology?